H. Lundbeck AS Ordinary Shares - Class B

HLUN B: XCSE (DNK)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|.cZLOCK|>YLOCK|Qp^SlWg

No-Moat Lundbeck's Strategic Brands Drive Sales, but Loss of Exclusivity Weighs on Long-Term Outlook

Business Strategy and Outlook

Lundbeck's portfolio focuses on central nervous system drugs, including antidepressants, antipsychotics, and antiepileptic products. While incremental innovations and label expansions helped Lundbeck earn excess returns over the past several years, this occurred before many of Lundbeck’s patents expired. Since then, generic entry has created significant competition and pricing pressure for the firm.

Sponsor Center